argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
835.99
-2.50 (-0.30%)
May 29, 2026, 4:00 PM EDT - Market closed
argenx SE Employees
argenx SE had 1,863 employees as of December 31, 2025. The number of employees increased by 264 or 16.51% compared to the previous year.
Employees
1,863
Change (1Y)
264
Growth (1Y)
16.51%
Revenue / Employee
$2,545,609
Profits / Employee
$799,267
Market Cap
51.98B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,863 | 264 | 16.51% |
| Dec 31, 2024 | 1,599 | 451 | 39.29% |
| Dec 31, 2023 | 1,148 | 305 | 36.18% |
| Dec 31, 2022 | 843 | 193 | 29.69% |
| Dec 31, 2021 | 650 | 314 | 93.45% |
| Dec 31, 2020 | 336 | 148 | 78.72% |
| Dec 31, 2019 | 188 | 83 | 79.05% |
| Dec 31, 2018 | 105 | 32 | 43.84% |
| Dec 31, 2017 | 73 | 15 | 25.86% |
| Dec 31, 2016 | 58 | 17 | 41.46% |
| Dec 31, 2015 | 41 | 9 | 28.13% |
| Dec 31, 2014 | 32 | 10 | 45.45% |
| Dec 31, 2013 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Vertex Pharmaceuticals | 6,400 |
| Moderna | 4,700 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Insmed | 1,664 |
ARGX News
- 2 days ago - argenx to Host Myositis R&D Webinar on June 23, 2026 - GlobeNewsWire
- 18 days ago - argenx SE Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 22 days ago - argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - GlobeNewsWire
- 23 days ago - argenx SE Earnings Call Transcript: Q1 2026 - Transcripts
- 23 days ago - argenx SE Earnings release: Q1 2026 - Filings
- 23 days ago - argenx SE Slides: Q1 2026 - Filings
- 24 days ago - argenx to Present at BofA Securities 2026 Health Care Conference - GlobeNewsWire
- 24 days ago - argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer - GlobeNewsWire